EA201692402A1 - Лекарственные формы для местного применения и их использование - Google Patents

Лекарственные формы для местного применения и их использование

Info

Publication number
EA201692402A1
EA201692402A1 EA201692402A EA201692402A EA201692402A1 EA 201692402 A1 EA201692402 A1 EA 201692402A1 EA 201692402 A EA201692402 A EA 201692402A EA 201692402 A EA201692402 A EA 201692402A EA 201692402 A1 EA201692402 A1 EA 201692402A1
Authority
EA
Eurasian Patent Office
Prior art keywords
dosage forms
local application
medical forms
conditions
methods
Prior art date
Application number
EA201692402A
Other languages
English (en)
Inventor
Сидни Л. Вайсс
Original Assignee
Окьюлар Текнолоджис Сарл
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54554700&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201692402(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Окьюлар Текнолоджис Сарл filed Critical Окьюлар Текнолоджис Сарл
Publication of EA201692402A1 publication Critical patent/EA201692402A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Abstract

Изобретение включает лекарственные формы для местного применения, такие как офтальмологические лекарственные формы, и способы использования таких лекарственных форм. В некоторых аспектах и вариантах такие лекарственные формы могут включать полиоксил липид или жирную кислоту и/или полиалкоксилированный спирт и могут включать наномицеллы. Также включены способы лечения или профилактики заболеваний или патологических состояний, таких как глазные болезни или патологические состояния.
EA201692402A 2014-05-23 2015-05-20 Лекарственные формы для местного применения и их использование EA201692402A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462002682P 2014-05-23 2014-05-23
PCT/US2015/031788 WO2015179527A1 (en) 2014-05-23 2015-05-20 Topical formulations and uses thereof

Publications (1)

Publication Number Publication Date
EA201692402A1 true EA201692402A1 (ru) 2017-03-31

Family

ID=54554700

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201692402A EA201692402A1 (ru) 2014-05-23 2015-05-20 Лекарственные формы для местного применения и их использование

Country Status (13)

Country Link
US (2) US20170065611A1 (ru)
EP (1) EP3145549A4 (ru)
JP (1) JP2017519813A (ru)
CN (1) CN106794254A (ru)
AU (1) AU2015264181A1 (ru)
BR (1) BR112016027379A2 (ru)
CA (1) CA2949954A1 (ru)
EA (1) EA201692402A1 (ru)
HK (1) HK1231376A1 (ru)
IL (1) IL248934A0 (ru)
MX (1) MX2016015211A (ru)
SG (1) SG11201609742VA (ru)
WO (1) WO2015179527A1 (ru)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3050298A1 (en) 2012-08-24 2014-02-27 Sun Pharma Global Fze Ophthalmic formulation of polyoxyl lipid or polyoxyl fatty acid and polyalkoxylated alcohol for use in the treatment of ocular conditions
ES2584534B1 (es) * 2015-03-27 2017-03-13 Retinset, S.L. Formulación tópica oftálmica de bosentan
JP7072517B2 (ja) * 2016-02-29 2022-05-20 サン ファーマ グローバル エフゼットイー 局所用シクロスポリン含有製剤およびその使用
WO2017152129A2 (en) * 2016-03-03 2017-09-08 Ocular Technologies Sarl Treatment of glaucoma and/or retinal diseases and formulations useful therefore
WO2018001445A1 (en) * 2016-07-01 2018-01-04 Pharmathen S.A. Process for preparing pharmaceutical ophthalmic compositions of brinzolamide
WO2022232586A1 (en) * 2021-04-30 2022-11-03 Perfuse Therapeutics, Inc. Treatment of ocular diseases using endothelin receptor antagonists

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7678836B2 (en) * 1999-11-04 2010-03-16 Fxs Ventures, Llc Method for rendering a contact lens wettable
US20040213782A1 (en) * 2003-02-03 2004-10-28 Pharmacia Corporation Compositions of an aquaporin modulating agent and an aqueous humor modulating agent for the treatment of elevated intraocular pressure
WO2007011880A2 (en) * 2005-07-18 2007-01-25 Minu, L.L.C. Enhanced ocular neuroprotection/neurostimulation
ES2511840T3 (es) * 2007-08-29 2014-10-23 Wakamoto Pharmaceutical Co., Ltd. Composición farmacéutica acuosa que contiene latanoprost
MX2007011165A (es) * 2007-09-12 2009-03-11 Arturo Jimenez Bayardo Composición farmacéutica estable de timolol, dorzolamida y brimonidina.
TWI544927B (zh) * 2008-03-17 2016-08-11 愛爾康研究有限公司 具有低濃度的表面活性劑以促進治療劑之生物可利用性的藥學組成物
JP2010037327A (ja) * 2008-07-07 2010-02-18 Wakamoto Pharmaceut Co Ltd ブリンゾラミド水性組成物
US9095506B2 (en) * 2008-11-17 2015-08-04 Allergan, Inc. Biodegradable alpha-2 agonist polymeric implants and therapeutic uses thereof
CA2773597A1 (en) * 2009-09-17 2011-03-24 Senju Pharmaceutical Co., Ltd. Latanoprost-containing aqueous eye drops and method for inhibiting adsorption of latanoprost to resin
WO2013025696A1 (en) * 2011-08-15 2013-02-21 Teva Pharmaceutical Industries Ltd. Ophthalmic formulations and processes for their preparation
IN2014MN02236A (ru) * 2012-05-11 2015-07-24 Cipla Ltd
CA3050298A1 (en) * 2012-08-24 2014-02-27 Sun Pharma Global Fze Ophthalmic formulation of polyoxyl lipid or polyoxyl fatty acid and polyalkoxylated alcohol for use in the treatment of ocular conditions

Also Published As

Publication number Publication date
EP3145549A4 (en) 2018-02-14
IL248934A0 (en) 2017-01-31
CA2949954A1 (en) 2015-11-26
JP2017519813A (ja) 2017-07-20
MX2016015211A (es) 2017-06-20
SG11201609742VA (en) 2016-12-29
AU2015264181A1 (en) 2016-12-01
HK1231376A1 (zh) 2017-12-22
US20180092927A1 (en) 2018-04-05
CN106794254A (zh) 2017-05-31
BR112016027379A2 (pt) 2018-06-26
EP3145549A1 (en) 2017-03-29
WO2015179527A1 (en) 2015-11-26
US20170065611A1 (en) 2017-03-09

Similar Documents

Publication Publication Date Title
EA201890725A1 (ru) Агонисты фарнезоидного х-рецептора и их применение
CO2017004715A2 (es) Métodos y formulaciones para tratar enfermedades vasculares de los ojos
EA201790273A1 (ru) Флагеллиновые композиции и их применение
EA201792354A1 (ru) Композиции обетихолевой кислоты и способы применения
EA201691872A1 (ru) Гетероциклические соединения для применения в лечении pi3k-гамма-опосредованных расстройств
EA201500314A1 (ru) Лекарственные формы энзалутамида
EA201692301A1 (ru) Производные бороновой кислоты и их терапевтическое применение
EA201692402A1 (ru) Лекарственные формы для местного применения и их использование
EA201791516A1 (ru) Способы комбинированного лечения злокачественных опухолей
EA201690881A1 (ru) Соединения-ингибиторы аутотаксина
EA201790575A1 (ru) Триазолопиразиноны в качестве ингибиторов pde1
EA201391416A1 (ru) Новые соединения в качестве модуляторов протеинкиназ
CL2014000432A1 (es) Compuestos derivados de clorofila o bacterioclorofila; composicion farmaceutica que los comprende; y metodo de tratamiento fotodinamico del adelgazamiento de la cornea o del estiramiento de la esclerotica.
EA201792157A1 (ru) Имидазопиразиноны в качестве ингибиторов pde1
EA201790787A1 (ru) Снижение вязкости фармацевтических составов
MX2017005861A (es) Metodos para el control transcripcional objetivo en regiones del super mejorador.
EA201892265A1 (ru) Способы лечения офтальмологических заболеваний
EA201690039A1 (ru) Ингибиторы rorc2 и способы их применения
EA202091865A1 (ru) Композиции и способы для снижения экспрессии tau
EA201501054A1 (ru) Лечение миопатий и нейродегенеративных заболеваний, связанных с агрегацией белков, путём парентерального введения трегалозы
EA201792571A1 (ru) Терапевтическое применение l-4-хлорокинуренина
EA201600288A1 (ru) Замещенные фенилаланиновые производные
EA201692111A1 (ru) Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний
ZA201703467B (en) Methods of treating ocular conditions
EA201790699A1 (ru) Стабилизированные производные адреномедуллина и их применение